The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S3-S13 , February 2009

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

  • Ethel S. Siris, MD

      Affiliations

    • Toni Stabile Osteoporosis Center and the Metabolic Bone Diseases Program, Department of Medicine, Columbia University Medical Center, New York, New York, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Ethel S. Siris, MD, Toni Stabile Osteoporosis Center, Department of Medicine, Columbia University Medical Center, 180 Fort Washington Avenue, New York, New York 10032
    • ,
  • Peter L. Selby, MD

      Affiliations

    • Department of Medicine, Manchester Royal Infirmary, Manchester, England, United Kingdom
    • ,
  • Kenneth G. Saag, MD

      Affiliations

    • Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    • ,
  • Fredrik Borgström, PhD

      Affiliations

    • Medical Management Center, Karolinska Institute, Stockholm, Sweden
    • i3 Innovus, Stockholm, Sweden
    • ,
  • Ron M.C. Herings, PhD

      Affiliations

    • PHARMO Institute, Utrecht, Netherlands
    • ,
  • Stuart L. Silverman, MD

      Affiliations

    • David Geffen School of Medicine, University of California–Los Angeles, Los Angeles, California, USA

References 

  1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465–475
  2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733
  3. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(suppl 1):S4–S9
  4. Rousculp MD, Long SR, Wang S, Schoenfeld MJ, Meadows ES. Economic burden of osteoporosis-related fractures in Medicaid. Value Health. 2007;10:144–152
  5. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822
  6. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018–2026
  7. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47
  8. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–1008
  9. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922–928
  10. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271–287
  11. Siris ES, Harris ST, Rosen CJ. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–1022
  12. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711–719
  13. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–1031
  14. Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? (Adherence issues with bisphosphonate therapy). Ann Pharmacother. 2006;40:1143–1150
  15. Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep. 2006;4:21–27
  16. Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007;23:585–594
  17. Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19:511–517
  18. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin. 2006;22:1757–1764
  19. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int. 2007;18:271–277
  20. Lekkerkerker F, Kanis JA, Alsayed N, et al. Group for the Respect of Ethics and Excellence in Science (GREES) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18:1311–1317
  21. Curtis JR, Westfall A, Cheng H, Delzell E, Lyles K, Saag KG. Longitudinal patterns of adherence with bisphosphonates. Presented at the American Society for Bone and Mineral Research 29th Annual Meeting; September 16-20, 2007; Honolulu, Hawaii. Abstract S440.⁎
  22. Goettsch WG, Penning F, Erkens JE, Lynch NO, Novak A, Herings RMC. Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fractures. J Bone Miner Res. 2005;20(suppl 1):S278;Abstract SU388
  23. Sebaldt RJ, Shane LG, Pham BZ, et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis. J Bone Miner Res. 2004;19(suppl 1):S445;Abstract M423
  24. Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone. 2007;41:882–887
  25. Jaglal S, Thiruchelvam D, Hawker G. Impact of adherence to osteoporosis medications on fracture rates: a population-based study. Presented at the American Society for Bone and Mineral Research 29th Annual Meeting; September 16-20, 2007; Honolulu, Hawaii. Abstract 1275.
  26. Curtis JR, Westfall A, Cheng H, Delzell E, Lyles K, Saag KG. Bisphosphonates adherence and fracture risk: time-dependent relationships from 103,038 users. Presented at the American Society for Bone and Mineral Research 29th Annual Meeting; September 16-20, 2007; Honolulu, Hawaii. Abstract M444.⁎
  27. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811–818
  28. Gothe H, Hadji P, Hoeer A, Storz P, Olson M, Haeussler B. Good persistence and adherence with oral bisphosphonates reduce fracture rate in patients with osteoporotic fractures. Calcif Tissue Int. 2007;80(suppl 1):S129;Abstract P345-S
  29. Briesacher BA, Andrade S, Kahler K, Yood R. Economic impact of the previous year's adherence with bisphosphonates. Poster presentation at the American Society for Bone and Mineral Research 28th Annual Meeting; September 15-19, 2006; Philadelphia, Pennsylvania. Abstract SA300.
  30. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3–12
  31. Cooper A, Drake J, Brankin E PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60:896–905
  32. Orsini LS, Rousculp MD, Long SR, Wang S. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int. 2005;16:359–371
  33. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15
  34. Kuehn BM. Better osteoporosis management a priority: impact predicted to soar with aging population. JAMA. 2005;293:2453–2458
  35. Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J. 2007;100:1214–1218

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)01190-X

doi: 10.1016/j.amjmed.2008.12.002

The American Journal of Medicine
Volume 122, Issue 2, Supplement , Pages S3-S13 , February 2009

Article Tools